HOME >> MEDICINE >> NEWS
HIV vaccine trial breaks ground for future research

The results of the world's first phase 3 HIV vaccine efficacy trial are reported in the March 1 issue of The Journal of Infectious Diseases, now available online. Although the vaccine was ineffective in preventing HIV infection, the trial represents a landmark in the fight against HIV and offers the scientific community a foundation on which to build future trials.

The multi-centered trial, conducted in the United States and the Netherlands and completed in 2003, is described in two papers by the rgp120 HIV Vaccine Study Group, and Peter B. Gilbert and colleagues, which address the vaccine efficacy results and the immunologic responses of the study participants.

The vaccine, produced by VaxGen, was a recombinant construct of the HIV envelope glycoprotein, similar to the type of vaccine used to develop a vaccine for hepatitis B. The vaccine was tested in a double-blind, randomized study of healthy participants who did not use intravenous drugs. The volunteers were men who have sex with men or women at high risk for heterosexual transmission. The vaccine and placebo were given by injection seven times over 30 months and the participants were assessed for risk. At each visit the participants were tested for HIV infection, and for those who were positive, HIV-1 plasma RNA load and CD4 cell counts were monitored on a regular basis for 24 months after the initial diagnosis.

Of the 5,417 volunteers who were enrolled, 368 became infected during the study. The vaccine was found not to be effective in preventing HIV infection; infection rates among those who were given the vaccine and those who were given placebo were 6.7 percent and 7.0 percent, respectively. Of those who became infected during the study, pre-treatment viral loads were similar in the placebo and vaccine groups over their follow-up visits.

During analysis of various subgroups of the study population, a higher, though statistically insignificant, vaccine efficacy was found in th
'"/>

Contact: Steve Baragona
sbaragona@idsociety.org
703-299-0412
Infectious Diseases Society of America
3-Feb-2005


Page: 1 2

Related medicine news :

1. Pitt marks 50th anniversary of its Salk polio vaccine with reunion, scientific symposium
2. NIAID initiates trial of experimental avian flu vaccine
3. Study finds majority of women willing to accept cervical cancer vaccine for self and children
4. Invasive pneumonia and antibiotic resistance decreased after childhood vaccine introduced
5. Earlier use of prostate cancer vaccines urged by Hopkins scientists
6. Researchers close in on breast cancer vaccine
7. EuroVacc 02 HIV vaccine trial begins in February 2005
8. Varicella vaccine effective on chicken pox; Impact on herpes zoster unclear
9. Pathogen-mimicking vaccine as strategy for cancer therapy
10. First US kidney cancer vaccine trial underway at Columbia
11. NIAID begins enrolling volunteers for novel HIV vaccine study

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/8/2019)... ... December 07, 2019 , ... More than 85 million people ... report from the American Academy of Dermatology, indicating this problem is more common than ... during the years to come. These dermatological conditions vary in type and severity and ...
(Date:12/6/2019)... , ... December 06, 2019 , ... ... of assembling and manufacturing implantable medical devices, which is a new and rapidly ... name suggests, implantable medical devices are surgically inserted into various parts of the ...
(Date:12/6/2019)... ... December 06, 2019 , ... COMPLIANCY GROUP ... for the Wyoming Medical Society. Compliancy Group is dedicated to educating and assisting ... obligation to adhere to the standards set forth by the Health Insurance Portability ...
(Date:12/5/2019)... ... December 05, 2019 , ... Abide, the #1 Christian ... million times this year using Bible-based bedtime stories. Listeners have recovered from bad dreams ... to the Center for Disease Control, one third of Americans suffer from poor sleep, ...
(Date:12/4/2019)... ... December 04, 2019 , ... A November 12 article ... offer them as public transit options. The article highlighted the life-changing or life-ending consequences ... to a bed to a rider fatality after an incident with a vehicle. Los ...
Breaking Medicine News(10 mins):
(Date:12/5/2019)... (PRWEB) , ... December 05, 2019 , ... ... education planning, has announced the Top 27 Respiratory Therapy Degree Programs for 2020. ... and universities in the nation. Each program is evaluated based on curriculum quality, ...
(Date:12/4/2019)... ... December 04, 2019 , ... ... professionals with minimally invasive technologies to treat chronic pain in soft and hard ... Tenex Health TX® technology. , Dr. Bernard Morrey, Chief Medical Officer ...
(Date:12/2/2019)... (PRWEB) , ... December 02, 2019 , ... ... owner of A Mission for Michael, an intensive mental health facility, announced it ... to oversee client relations, business development and national advocacy efforts. , "We are ...
Breaking Medicine Technology:
Cached News: